Biotechnology atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression – ATAI Life Sciences (NASDAQ:ATAI) Read more
Biotechnology Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More – ATAI Life Sciences (NASDAQ:ATAI), Algernon Pharmaceuticals (OTC:AGNPF) Read more
Opinion Thinking about buying stock in Akebia Therapeutics, Mind Medicine, ATAI Life Sciences, Doma Holdings, or Iterum Therapeutics? – ATAI Life Sciences (NASDAQ:ATAI), Akebia Therapeutics (NASDAQ:AKBA) Read more
Biotechnology Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta’s Influence – ATAI Life Sciences (NASDAQ:ATAI), Clearmind Medicine (NASDAQ:CMND) Read more
Biotechnology Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline – Compass Pathways (NASDAQ:CMPS), ATAI Life Sciences (NASDAQ:ATAI) Read more
Biotechnology Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression – ATAI Life Sciences (NASDAQ:ATAI) Read more
Biotechnology Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana’s Research And More – ATAI Life Sciences (NASDAQ:ATAI), Clearmind Medicine (NASDAQ:CMND) Read more
Biotechnology Psychedelics Headlines: Substitution Survey, Frank Herbert’s Magic Mushrooms, Celestial Plans And News Review – ATAI Life Sciences (NASDAQ:ATAI), BetterLife Pharma (OTC:BETRF) Read more
Opinion Thinking about buying stock in Lexicon Pharmaceuticals, Cassava Sciences, Clearside Biomedical, Lantern Pharma, or ATAI Life Sciences? – Clearside Biomedical (NASDAQ:CLSD), ATAI Life Sciences (NASDAQ:ATAI) Read more
Cannabis Psyched: Suggestibility And Psychedelics’ Effects, EU’s $7M Research Fund, Australia’s Treatment Delivery, BZ Podcast And More – ATAI Life Sciences (NASDAQ:ATAI), Clearmind Medicine (NASDAQ:CMND) Read more
